Palatin Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Palatin Technologies şirketinin toplam hissedar öz sermayesi $-7.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $3.4M ve $11.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$2.38m
Eşitlik	-US$7.69m
Toplam yükümlülükler	US$11.10m
Toplam varlıklar	US$3.42m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0KF3 negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: 0KF3 şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0KF3 borçsuzdur.

Borcun Azaltılması: 0KF3 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0KF3 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 0KF3 un, serbest nakit akışı her yıl % 32.8 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Palatin Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Technologies Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Receives Notice of Non-Compliance from NYSE American

Recent updates

Palatin Technologies, Inc. Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

First quarter 2025 earnings released: US$0.39 loss per share (vs US$0.48 loss in 1Q 2024)

Palatin Technologies, Inc. to Report Q1, 2025 Results on Nov 14, 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule Pl7737 Obesity Program at Obesityweek 2024

Palatin Technologies, Inc. Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Palatin Technologies, Inc. Presents Illustrates Data from Clinical and Preclinical Studies for Three Proprietary Melanocortin Agonists

Palatin Receives Notice of Non-Compliance from NYSE American

New major risk - Revenue and earnings growth

Full year 2024 earnings released: US$2.02 loss per share (vs US$2.21 loss in FY 2023)

Palatin Technologies, Inc. to Report Q4, 2024 Results on Oct 01, 2024

Palatin Technologies, Inc., Annual General Meeting, Dec 12, 2024

Palatin Technologies, Inc. Announces FDA Confirms Acceptability of Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Palatin Technologies, Inc. Announces First Patient Dosed in Phase 2 Clinical Study of Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

New major risk - Shareholder dilution

Forecast to breakeven in 2027

Palatin Technologies, Inc. Announces Initiation of Phase 2 Clinical Study of Bremelanotide Co-Administered with PDE5i for Treatment of Erectile Dysfunction

Palatin Technologies, Inc. Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

Palatin Technologies, Inc., Annual General Meeting, Jun 27, 2024

Third quarter 2024 earnings released: US$0.53 loss per share (vs US$0.63 loss in 3Q 2023)

Palatin Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024

Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease (Ded) Clinical Data Results Presented At American Society of Cataract and Refractive Surgery (Ascrs) 2024

No longer forecast to breakeven

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.13 loss in 2Q 2023)

Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $10.000006 million.

Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024

Forecast to breakeven in 2026

Palatin Technologies Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.86 loss in 1Q 2023)

New major risk - Negative shareholders equity

Palatin Technologies, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Palatin Technologies, Inc. announced that it expects to receive $5.000001 million in funding

Palatin Technoloes, Inc. Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Receives Notice of Non-Compliance from NYSE American

Full year 2023 earnings released: US$2.53 loss per share (vs US$3.79 loss in FY 2022)

Palatin Technologies, Inc. to Report Q4, 2023 Results on Sep 28, 2023

Insufficient new directors

Palatin Technologies, Inc. Completes Enrollment in Phase 3 Melody-1 Study of PL9643 for the Treatment of Patients with Dry Eye Disease

Palatin Technologies, Inc. Initiates Clinical Program for Bremelanotide Co-Formulated with A Pde5i for the Treatment of Ed in Patients Non-Responsive to Pde5i Treatment

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Palatin Technologies, Inc., Annual General Meeting, Jun 20, 2023

Third quarter 2023 earnings released: US$0.63 loss per share (vs US$0.80 loss in 3Q 2022)

Palatin Technologies, Inc. to Report Q3, 2023 Results on May 16, 2023

Palatin Technologies, Inc. Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

Insufficient new directors

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.91 loss in 2Q 2022)

Palatin Technologies, Inc. to Report Q2, 2023 Results on Feb 15, 2023

Insufficient new directors

Palatin Technologies Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

Forecast to breakeven in 2025

Insufficient new directors

Palatin Technologies, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $9.999921 million.

Palatin Technologies, Inc. Announces First Patient Has Been Enrolled in the Pl8177-205 Study with Palatin's Pl8177

Insufficient new directors

Full year 2022 earnings released: US$3.79 loss per share (vs US$3.55 loss in FY 2021)

Palatin Technologies, Inc. to Report Q4, 2022 Results on Sep 22, 2022

Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

Palatin Technologies, Inc. Announces Appointment of Carl Spana as Chief Executive Officer Effective July 1, 2022

Insufficient new directors

Palatin Technologies, Inc., Annual General Meeting, Jun 24, 2022

Third quarter 2022 earnings released: US$0.032 loss per share (vs US$0.024 loss in 3Q 2021)

Palatin Technologies, Inc. to Report Q3, 2022 Results on May 17, 2022

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Palatin Technologies, Inc. to Report Q2, 2022 Results on Feb 15, 2022